First PI3K Inhibitor for Breast Cancer

被引：4
|
作者：
Voelker, Rebecca
机构：
来源：
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2019年 / 322卷 / 01期
关键词：
D O I：
10.1001/jama.2019.8916
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：19 / 19
页数：1
相关论文
共 50 条
  • [1] FDA approves first PI3K inhibitor
    不详
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2014, 13 (09) : 644 - 645
  • [2] FDA approves first PI3K inhibitor
    [J]. Nature Reviews Drug Discovery, 2014, 13 (9) : 644 - 645
  • [3] IMAGING CAN IDENTIFY PI3Kα-INHIBITOR SUSCEPTIBILITY IN BREAST CANCER
    不详
    [J]. CANCER DISCOVERY, 2020, 10 (12) : 1786 - 1786
  • [4] Lactate Lights up PI3K Inhibitor Resistance in Breast Cancer
    Hillis, Alissandra L.
    Toker, Alex
    [J]. CANCER CELL, 2020, 38 (04) : 441 - 443
  • [5] The impact of PI3K/AKT inhibitor on the radiosensitization of breast cancer cells
    Fu, S
    Zeng, QW
    Sun, Y
    Zhang, Q
    Shao, YH
    Jian, GL
    [J]. RADIOTHERAPY AND ONCOLOGY, 2006, 78 : S93 - S93
  • [6] First-in-class PI3K inhibitor advances
    不详
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2013, 12 (11) : 817 - 817
  • [7] First-in-class PI3K inhibitor advances
    [J]. Nature Reviews Drug Discovery, 2013, 12 : 817 - 817
  • [8] PI3K Inhibitors in Breast Cancer Therapy
    Ellis, Haley
    Ma, Cynthia X.
    [J]. CURRENT ONCOLOGY REPORTS, 2019, 21 (12)
  • [9] PI3K Inhibitors in Breast Cancer Therapy
    Haley Ellis
    Cynthia X. Ma
    [J]. Current Oncology Reports, 2019, 21
  • [10] PI3Kα/δ inhibitor, copanlisib is highly effective in ER-positive breast cancer
    De, Pradip
    Aske, Jennifer C.
    Williams, Casey
    Dey, Nandini
    Leyland-Jones, Brian
    [J]. CANCER RESEARCH, 2019, 79 (13)
12345